Physiogenex, a preclinical Contract Research Organization providing CRO services for developing drugs targeting obesity/type 2 diabetes and related comorbidities (NASH, CKD and CVD), will be presenting at the 19th World Congress of Insulin Resistance, Diabetes & Cardiovascular Disease in Los Angeles, CA, Dec. 2-4 2021.

Physiogenex to present its obese NASH hamster model for severe COVID-19 at the 19th WCIRDC in Los Angeles, CA

Dr. François Briand, Director of Research and Business Development, will be presenting an abstract entitled “Diet-induced obesity and NASH aggravate SARS-CoV-2 infection in golden Syrian hamsters”.

The abstract will be presented during the poster session to be held on December the 2nd, 6:30pm-7:30pm, and during the abstract oral presentation session to be held on December the 3rd, 7:30pm-9pm.

If you wish to set an appointment with Dr. François Briand to discuss about your preclinical project, please contact us.

About the 19th WCIRDC

please visit meeting website

About Physiogenex

Physiogenex is a leading preclinical research organization providing non-clinical services in metabolic disorders and complications.

We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We have a strong expertise on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis) and renal complications.